Vector BioMed Launches in Maryland with Gene Therapy Industry Veteran at Helm to Address the Vector Supply Bottleneck with End-to-End Solutions Platform

Published on :

Biomanufacturing Company Vector BioMed Launches with Mission to Provide Access to High-Quality Lentiviral Vectors and Address the Vector Supply Bottleneck
Vector BioMed
Jan 31, 2023, 07:30 ET
First Round Funding Led by Viking Global Investors and Casdin Capital
Boro Dropulić, Ph.D., MBA, named Chief Executive Officer of Vector BioMed
GAITHERSBURG, Md., Jan. 31, 2023 /PRNewswire/ — Vector BioMed, a biomanufacturing company specializing in the manufacture of lentiviral vectors, today announced its launch and first financing round led by Viking Global Investors and Casdin Capital. The funds will support the acceleration of commercial operations to provide rapid access to high-quality lentiviral vectors for pre-clinical development, clinical trials, and commercialization.
In contrast to traditional contract development and manufacturing organizations (CDMOs), Vector BioMed is a solution provider that will provide partners with the capabilities to take their lentiviral vector-based medicinal concepts into the clinic and accelerate their path to commercialization. Vector BioMed will help address the industry’s current vector supply bottleneck by providing lentiviral vectors at scale, while also offering turnkey solutions for vector design and optimization, pre-clinical manufacturing, GMP manufacturing, and other support services.
In conjunction with the funding and launch, co-founder Boro Dropulić, Ph.D., MBA has…

Despite Strong 2021 Performance Headwinds Remain for Biosimilars Uptake

Published on :

Biosimilars, also known as follow-on biologics, continued to capture greater market share and foment stronger competition with reference or brand name drugs in 2021. Increasing the number of biosimilars in the market and amplifying uptake by payers, family medical practices and pharmacies could be a gamechanger for patients and a healthcare system trying to reduce the cost of life-changing medicines.

“There’s Gold in Them Thar Hills!” – VC Funding Floods BioHealth Capital Region in 2021

Photo of gold bars
Published on :

In the third quarter of 2021 alone, more than $400 million of private capital was invested in Maryland businesses. The money went to more than 34 different companies, according to data compiled by PitchBook. The deals brought the state to about $1.6 billion in funding for the first three-fourths of the year and placed Maryland on track to bring in about $2 billion worth of VC funding for the year. That was a significant jump over 2020, when Maryland saw about $1.26 billion in VC funding. For the industry at large in 2020, VC activity in biotechs grew by 45% to $36.6 billion.

BioHealth Capital Region Retains Strong Grip on No. 4 Spot of Top 10 U.S. Biopharma Hubs Eyes Third Spot by 2023

BioHealth Capital Region growth
Published on :

As a life sciences cluster, the BioHealth Capital Region is poised to become a top-three cluster in the Genetic Engineering & Biotechnology News (GEN) Top 10 Biopharma Clusters ranking on the strengths of early-stage companies becoming commercial successes and the construction of millions of square feet of new wet lab space.

Big Bio and Big Data to Converge at the 7th Annual BioHealth Capital Region Forum

Published on :

The 7th annual BioHealth Capital Region (BHCR) Forum will be held virtually again in 2021 with a small change. This year the Forum will be split between two half-days held on September 13th and 14th. With the theme of “Big Bio…Big Data…Converging”, the Forum will bring together the top biotech and life science executives and expert speakers from across the industry, academia, healthcare, government, finance, and real estate development, among others, to discuss this emerging space in BioHealth.

2021 Mid-Atlantic Science and Technology Virtual Showcase

Published on :

The ISPE Chesapeake Bay Area Chapter Mid-Atlantic Science & Technology (MAST) Virtual Showcase, hosted on May 19th, 2021, provided a platform for life science companies to discuss strategies for addressing challenges in the life science industry.

Fifty Years: The Journey from PhD to VC

BioTech Venture Capital
Published on :

With the availability of academic positions on the decline, and a boom in startups resulting from disruptive technologies, some PhDs are looking to utilize their unique set of skills in a slightly nontraditional way – venture capitalism (VC). One VC firm, called Fifty Years, has recently concluded its inaugural program (PhD to VC), which aimed at preparing young scientists with the skills needed to jumpstart their VC careers.

BioHealth Capital Region Women Making Waves in Venture Capital

Published on :

Improving access to venture capital for life science entrepreneurs and emerging biopharma companies in the BioHealth Capital Region (BHCR) is a top priority. However, elevating the region’s funding profile is not the only type of access undergoing a transformation in recent years.